Suppr超能文献

概述目前可用于治疗 COVID-19 的方法以及大流行期间使用抗生素的影响。

An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic.

机构信息

Departamento de Áreas Acadêmicas, Instituto Federal de Educação, Ciência e Tecnologia de Goiás, Campus Goiânia Oeste, Goiânia, GO, Brasil.

Instituto Federal de Educação, Ciência e Tecnologia de Goiás, Campus Valparaíso, Valparaíso, GO, Brasil.

出版信息

Braz J Med Biol Res. 2021 Dec 10;55:e11631. doi: 10.1590/1414-431X2021e11631. eCollection 2021.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused several problems in healthcare systems around the world, as to date, there is no effective and specific treatment against all forms of COVID-19. Currently, drugs with therapeutic potential are being tested, including antiviral, anti-inflammatory, anti-malarial, immunotherapy, and antibiotics. Although antibiotics have no direct effect on viral infections, they are often used against secondary bacterial infections, or even as empiric treatment to reduce viral load, infection, and replication of coronaviruses. However, there are many concerns about this therapeutic approach as it may accelerate and/or increase the long-term rates of antimicrobial resistance (AMR). We focused this overview on exploring candidate drugs for COVID-19 therapy, including antibiotics, considering the lack of specific treatment and that it is unclear whether the widespread use of antibiotics in the treatment of COVID-19 has implications for the emergence and transmission of multidrug-resistant bacteria.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染在全球医疗体系中引发了诸多问题,因为迄今为止,尚无针对所有形式的 COVID-19 的有效且特效的治疗方法。目前正在测试具有治疗潜力的药物,包括抗病毒药、抗炎药、抗疟药、免疫疗法和抗生素。尽管抗生素对病毒感染没有直接作用,但它们常被用于治疗继发性细菌感染,甚至作为经验性治疗以降低病毒载量、感染和冠状病毒的复制。然而,这种治疗方法存在诸多顾虑,因为它可能会加速和/或增加长期抗生素耐药性(AMR)的发生率。我们专注于探索 COVID-19 治疗的候选药物,包括抗生素,因为目前缺乏特效治疗方法,而且尚不清楚在 COVID-19 治疗中广泛使用抗生素是否会对多药耐药菌的出现和传播产生影响。

相似文献

1
An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic.
Braz J Med Biol Res. 2021 Dec 10;55:e11631. doi: 10.1590/1414-431X2021e11631. eCollection 2021.
3
Bacterial co-infections with SARS-CoV-2.
IUBMB Life. 2020 Oct;72(10):2097-2111. doi: 10.1002/iub.2356. Epub 2020 Aug 8.
4
5
Pathogenesis-directed therapy of 2019 novel coronavirus disease.
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
7
Antimicrobial resistance research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic.
J Glob Antimicrob Resist. 2021 Jun;25:5-7. doi: 10.1016/j.jgar.2021.02.013. Epub 2021 Mar 1.
8
Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance.
Trans R Soc Trop Med Hyg. 2021 Oct 1;115(10):1122-1129. doi: 10.1093/trstmh/trab048.
9
Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses.
Adv Exp Med Biol. 2021;1322:219-260. doi: 10.1007/978-981-16-0267-2_9.
10

引用本文的文献

2
Open Source Antibiotics: Simple Diarylimidazoles Are Potent against Methicillin-Resistant .
ACS Infect Dis. 2023 Dec 8;9(12):2423-2435. doi: 10.1021/acsinfecdis.3c00286. Epub 2023 Nov 22.
3
Variables Associated with 30-Day Mortality in Very Elderly COVID-19 Patients.
Clin Interv Aging. 2023 Jul 25;18:1155-1162. doi: 10.2147/CIA.S417282. eCollection 2023.
4
Genomic Characterization of Clinical Isolates Obtained from COVID-19 Patients in Russia.
Antibiotics (Basel). 2022 Mar 6;11(3):346. doi: 10.3390/antibiotics11030346.

本文引用的文献

4
Convalescent plasma therapy in COVID-19 critically ill patients during advanced phases of clinical trials and their preliminary results.
Einstein (Sao Paulo). 2021 Apr 19;19:eRW6186. doi: 10.31744/einstein_journal/2021RW6186. eCollection 2021.
6
Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy.
J Infect Public Health. 2021 May;14(5):570-576. doi: 10.1016/j.jiph.2021.02.001. Epub 2021 Feb 9.
7
Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study.
PLoS One. 2021 Mar 24;16(3):e0248276. doi: 10.1371/journal.pone.0248276. eCollection 2021.
8
Immunity, virus evolution, and effectiveness of SARS-CoV-2 vaccines.
Braz J Med Biol Res. 2021 Mar 15;54(5):e10725. doi: 10.1590/1414-431X202010725. eCollection 2021.
9
Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
Clin Exp Pharmacol Physiol. 2021 Jun;48(6):823-830. doi: 10.1111/1440-1681.13488. Epub 2021 Mar 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验